Fluoxetine Disappoints in Two New Stroke Trials Fluoxetine Disappoints in Two New Stroke Trials
The antidepressant failed to yield improvements in stroke recovery and was associated with an increase in fracture rates in the EFFECTS and AFFINITY studies.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 14, 2020 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Aurobindo Pharma gets USFDA nod for generic antidepressant tablets
The company has received the final approval from the US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine tablets in the strengths of 10 mg and 20 mg, Aurobindo Pharma said in a filing to BSE. The tablets are generic version of Eli Lilly's Prozac tablets, it added. The product will be launched in April 2020. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 8, 2020 Category: Pharmaceuticals Source Type: news
Serious shortage protocol (SSP) for Fluoxetine (England)
The Department of Health and Social Care (DHSC) have decided to issue a Serious Shortage Protocols (SSP)... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 12, 2020 Category: Drugs & Pharmacology Source Type: news
Podcast: Selective serotonin reuptake inhibitors for stroke recovery
Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.Stroke is a common cause of disability in the community. Although there have been major advances in the care of stroke patients over the last few years, many survivors are still left with physical disability, such as weakn...
Source: Cochrane News and Events - February 26, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Increased circulatory IL-6 during 8-week fluoxetine treatment is a risk factor for suicidal behaviors in youth - Amitai M, Taler M, Ben-Baruch R, Lebow M, Rotkopf R, Apter A, Fennig S, Weizman A, Chen A.
OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat anxiety and/or depression in pediatric populations. However, the response rates are low (approximately 50%). Moreover, SSRI use is frequently associated with adverse even... (Source: SafetyLit)
Source: SafetyLit - January 1, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Amendments to Serious Shortage Protocols for fluoxetine 30mg capsules (England)
The Serious Shortage Protocols (SSP) for fluoxetine 30mg capsules has been varied... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 20, 2019 Category: Drugs & Pharmacology Source Type: news
